# A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

> **NCT01946568** · PHASE1 · COMPLETED · sponsor: **Durata Therapeutics Inc., an affiliate of Allergan plc** · enrollment: 36 (estimated)

## Conditions studied

- Bacterial Infections.

## Interventions

- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT01946568
- **Lead sponsor:** Durata Therapeutics Inc., an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2015-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946568, "A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01946568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*